Quest Diagnostics Settles Incentive Claims and Declares Dividend

Quest Diagnostics reached an agreement on November 6, 2026, to pay 13.014576 million US dollars to resolve claims regarding improper incentives provided to healthcare providers and executives. According to a Morningstar report citing Dow Jones Newswires, the settlement requires the Secaucus, New Jersey-based diagnostics provider to operate under a federal Corporate Integrity Agreement lasting five years.

The allegations involved entertainment offerings provided to healthcare executives from July 2013 to August 2022, including access to New York Giants suite tickets. Government authorities claimed these events aimed to produce patient referrals, leading to related diagnostic tests being billed to Medicare and Medicaid in New Jersey and New York. Quest stated that it denied all allegations and legal violations. The company explained that it had originally agreed to the resolution terms in 2025 to conclude the matter.

Alongside the regulatory resolution, Quest's Board of Directors declared a quarterly cash dividend of $0.86 per share on November 10, 2026. The payout is scheduled for distribution on January 27, 2027, to investors holding common stock as of the January 12, 2027 record date.

Following these updates, the company's shares closed at US$258.44, having achieved a 48.71% gain year to date and an 11.89% increase across the prior 30 days. On Lang & Schwarz, shares traded at 233.00 euros at 11:00 p.m. CET on Wednesday, November 11. The consensus Narrative on Simply Wall St indicated a fair value estimate of $253.73, suggesting the shares traded at a slight premium, while noting the company carried a price-to-earnings ratio of 25.3x compared to 26.1x for industry peers.

The compliance agreement introduces governance oversight as the company balances commercial growth against healthcare policy risks. While partnerships such as Apple Health and an expanded AD-Detect Alzheimer's portfolio featuring a late-2026 pTau217 assay add testing volume, potential payment reductions under the Protecting Access to Medicare Act continue to present regulatory challenges.